Abstract Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24‐week edaravone vs …

Abstract Introduction/Aims An intravenous (IV) formulation of edaravone has been shown to
slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS). An oral …

Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral
sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week …

Aim The study aims to increase understanding of edaravone's efficacy and safety as an
amyotrophic lateral sclerosis (ALS) treatment and provide significant insights regarding this …

We aimed to explore the longer-term efficacy and safety of edaravone in an active-treatment
extension period following the double-blind period of the second phase III study. Patients …

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative
disease. Although the pathogenesis remains unresolved, oxidative stress is known to play a …

Abstract Background and Objective The efficacy and safety of edaravone for the treatment of
amyotrophic lateral sclerosis (ALS) remain unclear. The aim of this meta-analysis was to …

Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

Background Based on the results of randomized, double-blind, placebo-controlled trials, the
benefit and safety of edaravone in the treatment of amyotrophic lateral sclerosis remain …

Our objective was to explore the efficacy and safety of edaravone in amyotrophic lateral
sclerosis (ALS) patients with a Japan ALS severity classification of Grade 3. In a 24-week …